| Literature DB >> 33603348 |
Abiy Tadesse Angelo1, Daniel Shiferaw Alemayehu1.
Abstract
BACKGROUND: Good adherence to antiretroviral therapy (ART) suppresses the viral load, reconstitutes the immune system, and decreases opportunistic infections among HIV-positive patients. However, adherence to ART is still challenging in developing countries such as Ethiopia. The study, therefore, aimed to assess adherence and its associated factors among HIV-positive patients on ART in southern Ethiopia in 2020.Entities:
Keywords: adherence; antiretroviral therapy; southwestern Ethiopia
Year: 2021 PMID: 33603348 PMCID: PMC7886248 DOI: 10.2147/PPA.S298594
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Socio-Demographic Characteristics of Patients Who Were on ART at GTSGH and MTUTH, Southwest Ethiopia, 2020
| Characteristics | Frequency | Percentage | |
|---|---|---|---|
| Age category | 18–28 | 73 | 22.2 |
| 29–39 | 144 | 43.8 | |
| 40–49 | 86 | 26.1 | |
| ≥50 | 26 | 7.9 | |
| Gender | Male | 158 | 48.0 |
| Female | 171 | 52.0 | |
| Marital status | Single | 61 | 18.5 |
| Married | 220 | 66.9 | |
| Divorced | 45 | 13.7 | |
| Widowed | 3 | 0.9 | |
| Living with family | Yes | 301 | 91.5 |
| No | 28 | 8.5 | |
| Residence | Urban | 254 | 77.2 |
| Rural | 75 | 22.8 | |
| Educational status | Cannot read and write | 57 | 17.3 |
| Able to read and write | 35 | 10.6 | |
| Primary school | 155 | 47.1 | |
| Secondary school | 57 | 17.3 | |
| Higher education | 25 | 7.6 | |
| Ethnicity | Kaffa | 193 | 58.7 |
| Amhara | 57 | 17.3 | |
| Oromo | 11 | 3.3 | |
| Bench | 34 | 10.3 | |
| Sheko | 12 | 3.6 | |
| Others* | 22 | 6.7 | |
| Religion | Orthodox | 186 | 56.5 |
| Muslim | 52 | 15.8 | |
| Protestant | 85 | 25.8 | |
| Catholic | 6 | 1.8 | |
| Monthly income in ETB | <1000 | 125 | 38.0 |
| 1000–3000 | 122 | 37 | |
| >3000 | 82 | 25 | |
| Occupational status | Housewife | 92 | 28.0 |
| Farmer | 72 | 21.9 | |
| Government employee | 75 | 22.8 | |
| Merchant | 37 | 11.2 | |
| Student | 17 | 5.2 | |
| Sex worker | 8 | 2.4 | |
| Daily laborer | 28 | 8.5 | |
Note: Ethnicity others*: Tigre, Majang, Menit, Gurage.
Figure 1Comorbid types among patients who were on ART at GTSGH and MTUTH, southwest Ethiopia, 2020.
Clinical and Behavioral Characteristics of Patients Who Were on ART at GTSGH and MTUTH, Southwest Ethiopia, 2020
| Characteristics | Category | Frequency | Percentage |
|---|---|---|---|
| Comorbidity | Yes | 99 | 30.1 |
| No | 230 | 69.9 | |
| Duration of illness | <12 months | 26 | 7.9 |
| 12–24 months | 63 | 19.1 | |
| ≥25 months | 240 | 72.9 | |
| Family history of HIV | Yes | 124 | 37.7 |
| No | 205 | 62.3 | |
| Current WHO clinical stage | I | 296 | 90.0 |
| II | 24 | 7.3 | |
| III | 9 | 2.7 | |
| Initial CD4 category | <200 cells/mm | 147 | 44.7 |
| 200–499 cells/mm3 | 142 | 43.2 | |
| ≥500 cells/mm3 | 40 | 12.2 | |
| Current CD4 category | <200 cells/mm3 | 53 | 16.1 |
| 200–499 cells/mm3 | 151 | 45.9 | |
| ≥500 cells/mm3 | 125 | 38.0 | |
| Ever had side effects of ART | Yes | 277 | 84.2 |
| No | 52 | 15.8 | |
| Current side effects of ART | Yes | 13 | 4.0 |
| No | 316 | 96.0 | |
| Current ART regimen | TDF, 3TC, EFV | 291 | 88.4 |
| TDF, 3TC, NVP | 8 | 2.4 | |
| AZT, 3TC, NVP | 17 | 5.2 | |
| AZT, 3TC, EFV | 13 | 3.9 | |
| Who reminds to take ART | Self | 216 | 65.7 |
| Alarm | 78 | 23.7 | |
| Family members | 19 | 5.8 | |
| Radio/television | 16 | 4.9 | |
| Treatment other than ART | Yes | 31 | 9.4 |
| No | 298 | 90.6 | |
| Treatment other than ART | Traditional drug | 12 | 38.7 |
| Religious practice, eg, Tsebel | 19 | 61.3 | |
| Disclosure to family/others | Yes | 285 | 86.6 |
| No | 44 | 13.4 | |
| Current smoking | Yes | 14 | 4.3 |
| No | 315 | 95.7 | |
| Current alcohol drinking | Yes | 41 | 12.5 |
| No | 288 | 87.5 | |
| Ever had multiple sexual partners | Yes | 28 | 8.5 |
| No | 301 | 91.5 |
Abbreviations: TDF, tenofovir; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; AZT, zidovudine.
Figure 2Adherence levels of patients to ART at GTSGH and MTUTH, southwest Ethiopia, 2020.
Bivariate and Multivariate Logistic Regression Analysis for Factors Associated with Adherence to ART Among Patients in GTSGH and MTUTH, Southwest Ethiopia, 2020
| Variables | Category | Adherence Status to ART Care | COR (95% CI) | AOR (95% CI) | |
|---|---|---|---|---|---|
| Non-Adherent (%) | Adherent (%) | ||||
| Age category | 18–27 | 4 (7%) | 69 (25.2%) | 1 (ref.) | 1 (ref.) |
| 28–38 | 19 (34.5%) | 125 (45.6%) | 0.381 (0.125, 1.166) | 0.836 (0.108, 6.501) | |
| 39–49 | 31 (56.4%) | 55 (20.1%) | 0.103 (0.034, 0.309)* | 0.068 (0.008, 0.578)** | |
| ≥50 | 1 (1.8%) | 25 (9.1%) | 1.449 (0.155, 13.594) | 8.107 (0.190, 346.524) | |
| Sex | Male | 35 (63.6%) | 123 (44.9%) | 1 (ref.) | 1 (ref.) |
| Female | 20 (36.4%) | 151 (55.1%) | 2.148 (1.181, 3.910)* | 2.543 (0.885, 7.306) | |
| Residence | Urban | 24 (43.6%) | 230 (83.9%) | 6.752 (3.622, 12.588)* | 5.186 (1.732, 15.529)** |
| Rural | 31 (56.4%) | 44 (16.1%) | 1 (ref.) | 1 (ref.) | |
| Educational status | Unable to read and write | 21 (38.2%) | 36 (13.1%) | 0.234 (0.062, 0.876)* | 0.097 (0.012, 0.771)** |
| Able to write and read without formal education | 13 (23.6%) | 22 (8%) | 0.231 (0.058, 0.924)* | 0.056 (0.006, 0.532)** | |
| Primary education | 11 (20%) | 144 (52.6%) | 1.785 (0.461, 6.908) | 0.902 (0.126, 6.451) | |
| Secondary education | 7 (12.7%) | 50 (18.2%) | 0.974 (0.230, 4.121) | 0.216 (0.019, 2.461) | |
| Higher education | 3 (5.5%) | 22 (8.1%) | 1 (ref.) | 1 (ref.) | |
| Smoking | Yes | 4 (7.3%) | 10 (3.6%) | 0.483 (0.146, 1.600)* | 0.811 (0.081, 8.097) |
| No | 51 (92.7%) | 264 (96.4%) | 1 (ref.) | 1 (ref.) | |
| Duration of illness | <12 months | 2 (3.6%) | 24 (8.7%) | 1 (ref.) | 1 (ref.) |
| 12–24 months | 12 (21.8%) | 51 (18.7%) | 0.354 (0.073, 1.709)* | 0.240 (0.007, 8.069) | |
| ≥25 months | 41 (74.6%) | 199 (72.6%) | 0.404 (0.092, 1.779)* | 0.198 (0.007, 5.359) | |
| Comorbidity | Yes | 43 (78.2%) | 56 (20.4%) | 0.072 (0.035, 0.145)* | 0.042 (0.013, 0.139)** |
| No | 12 (21.8%) | 218 (79.6%) | 1 (ref.) | 1 (ref.) | |
| Disclosure of HIV | Yes | 39 (70.9%) | 246 (89.8%) | 3.604 (1.788, 7.266)* | 3.583 (1.008, 12.739)** |
| No | 16 (29.1%) | 28 (10.2%) | 1 (ref.) | 1 (ref.) | |
| WHO clinical stage | Stage I | 36 (65.5%) | 260 (94.9%) | 1 (ref.) | 1 (ref.) |
| Stage II | 13 (23.6%) | 11 (4%) | 0.117 (0.049, 0.281)* | 0.098 (0.021, 0.453)** | |
| Stage III | 6 (10.8%) | 3 (1.1%) | 0.069 (0.017, 0.289)* | 0.004 (0.001, 0.075)** | |
| Current CD4 category | <200 cells/mm | 13 (23.6%) | 40 (14.6%) | 1 (ref.) | 1 (ref.) |
| 200–499 cells/mm3 | 29 (52.7%) | 122 (44.5%) | 1.367 (0.649, 2.881) | 0.853 (0.237, 3.066) | |
| ≥500 cells/mm3 | 13 (23.6%) | 112 (40.9%) | 2.800 (1.198, 6.546)* | 5.634 (1.203, 26.383)** | |
| Treatment other than ART | Yes | 13 (23.6%) | 18 (6.6%) | 0.227 (0.104, 0.498)* | 1.161 (0.277, 4.861) |
| No | 42 (76.4%) | 256 (93.4%) | 1 (ref.) | 1 (ref.) | |
Notes: *Significantly associated at p<0.25; **significantly associated at p<0.05.
Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; COR, crude odds ratio; CI, confidence interval; CD4, cluster of differentiation 4; HIV, human immunodeficiency virus.